Dimitris N. Mihailidis, PhD, FAAPM, FACMP, FASTRO, is an Associate Professor of Radiation Oncology at the University of Pennsylvania, where he serves as Director of the Medical Physics Graduate Programs. He previously led Penn Medicine’s Clinical Physics and Network Physics operations. He has held prominent roles within the AAPM, including Board Member‑at‑Large, Chair of the Therapy Physics Committee, Co‑Chair of TG‑203, and Chair of TG‑359. He has authored over 150 peer‑reviewed publications and multiple book chapters, contributing extensively to the advancement of medical physics. He has also mentored numerous graduate students, residents, and trainees across medical physics and radiation oncology.

Martin Gotthardt studied medicine at the Philipps-University in in Marburg (Germany) and after graduation, he defended his thesis on the metabolism of glucagon-like peptide 1 (GLP-1) in 1996. He was trained as a nuclear medicine specialist from 1997 to 2001 and then continued to work as a nuclear medicine staff physician at the Philipps-University of Marburg medical center. In 2005, he started a new position at the Department of Medical Imaging at the Radboud university medical center, Nijmegen (The Netherlands).  He is specialized on translational development and clinical validation of radiotracers. He has received funding from the National Institutes of Health (USA), DFG (D), BreakthroughT1D (NL) , ZonMW (NL)  and others and was/is coordinator of the collaborative EU projects BetaImage, BetaCure, BetaTrain and LightCure. Under his supervision, exendin derivatives have been introduced for non-invasive imaging of pancreatic beta cells in clinical research, recently this technology taken up in clinical guidelines. In addition, his research has focused on cancer imaging and therapy, including the development of quantitative SPECT for dosimetry, and development of innovative therapies for endocrine and chronic inflammatory diseases. In 2007, he was appointed extraordinary professor at the Philipps-University of Marburg, Germany. Since 2011, he holds a full chair for Experimental Nuclear Medicine at the Radboud University Nijmegen.

Xun Jia, PhD, FAAPM, FAIMBE, is a Professor and Chief of the Medical Physics Division in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. He also serves as Director of the Medical Physics Education Program and Co-Lead of the Cancer Imaging and Image-Guided Therapy Program within the Sidney Kimmel Comprehensive Cancer Center. His research focuses on AI-driven treatment planning, advanced medical imaging, and GPU-accelerated physics-based modeling. Dr. Jia leads multiple NIH-funded projects and international collaborations, and is actively involved in professional leadership through professional societies and editorial roles in major journals.

I am a medical physicist and senior scientist from Switzerland. My core expertise is in beam delivery, applied to photon C-arm linacs and proton gantries. My research activities focus on clinical implementation of new radiobiological concepts in clinical practice, focusing on spatially fractionated radiotherapy and ultra-high dose rates treatments (FLASH irradiations). I love working alongside clinicians, biologists and technicians, and with them trying to test the limits of conventional concepts. I also have expertise in innovative treatments for motion mitigation and treatments of moving tumors with protons

I completed my studies in Medical Physics in 2015, following research at Italian National Institute of Health focused on preclinical MR imaging. Since then, I have specialized in quantitative MRI for clinical body and neuro applications. I have also gained significant experience in radiotherapy, mainly in imaging application in RT and adaptive radiotherapy. I am currently responsible for the medical physics aspects of the MRI-Linac recently installed in our institution. I have authored over 30 peer-reviewed publications, coordinate the AIFM-Working Group on MRI Quantification, and served as Scientific Chair for the 2024 EFOMP-AIFM course on Quantitative MRI. 

Danielle Kalkman is an enthusiastic and dedicated educational consultant with extensive experience in designing and improving evidence‑based learning trajectories. With a background in educational sciences and a career spanning medical education, professional development, and curriculum innovation, she has contributed to high‑quality learning at institutions such as Radboudumc Health Academy and the Dutch Expert Centre for Screening (LRCB). Danielle excels at translating research‑based insights into practical, impactful learning solutions. 

She is a member of the EFOMP Education and Training Committee and an educational advisor for the EUTEMPE consortium.

Ioannis Tsougos, is Professor of Medical Physics at the University of Thessaly (Greece) and and Visiting Fellow at the Department of Neuroimaging, King’s College London (UK). He serves as Director of the Laboratory of Medical Informatics & Biomedical Imaging Applications, where his research focuses on MR physics and quality, quantitative and hybrid imaging, and AI-enabled image analysis. He also serves on European boards and working groups in MRI quality and safety (Convener of the MRI Special Interest Group) and has published extensively in peer-reviewed journals and books, including the authorship of an international textbook in advanced MR neuroimaging. Prof. Tsougos leads the MSc “Biomedical Imaging & Radiation Protection,” has extensive teaching experience in MRI/QC, and is active in curriculum reform and medical education innovation. He has received multiple distinctions and awards for his academic, clinical, and educational work. Indicatively, he was awarded the British Alumni UK Education Award for Social Action (2025) by the British Embassy in Greece.

Dr. Irene Torres-Espallardo is a certified medical physicist with over 25 years of experience in the field of medical physics, primarily dedicated to addressing the clinical needs of Nuclear Medicine Department.

Her research career has focused on the development of PET prototypes, corrections for quantitative imaging, and the optimization of acquisition protocols in molecular imaging. Her PhD was focused on image reconstruction for a small animal PET scanner (MADPET-II). She took part of the european ENVISION Project, dedicated to the development of the quality assurance tools for hadrondtherapy by means of PET and Compton Camera. More recently, her work has expanded to improving the accuracy of dosimetric calculations in radionuclide therapies within theragnostic procedures, with the aim of advancing personalized medicine in clinical practice.

Within the Nuclear Medicine Department of the Medical Imaging Clinical Area, Dr. Torres-Espallardo has coordinated the clinical validation of several prototypes, including PROSPET and CareMiBrain. She is currently involved in the evaluation of emerging technologies such as IMAS (total-body PET) and Helmet (a dedicated brain PET system).

She is also a key participant in the European project AIDER (EURATOM programme), which aims to develop a specialized imaging tool based on Compton camera technology to enhance imaging in targeted radionuclide therapies and enable image-based dosimetry in targeted alpha therapy.

In addition, Dr. Torres-Espallardo coleads the Nuclear Medicine domain within Work Package on High-Technology Medical Resources of the Joint Action JANE-2. This European initiative builds on the achievements of the previous JANE project (2022–2024) and aims to establish seven new Networks of Expertise over the next four years. These networks focus on cross-cutting aspects of cancer care, including complex and poor-prognosis cancers, palliative care, survivorship, personalized primary and secondary prevention, omics technologies, high-technology medical resources, and adolescents and young adults with cancer. Current efforts are directed toward defining present and future expansions in the use of nuclear medicine and their implications for equitable access across Europe.

Iuliana Toma-Dasu studied Medical Physics at Umeå University, Sweden, where she also became a certified medical physicist and received a Ph.D. degree. In parallel with her involvement in the educational program for the medical physicists run at Stockholm University, her main research interests focus on biologically optimised adaptive radiation therapy, including particle therapy, modelling the tumour microenvironment and the risks from radiotherapy.

Desde la finalización de mi doctorado, he volcado mi investigación científica en el área de la radioterapia adaptativa basada en imágenes funcionales, tanto de medicina nuclear como de resonancia magnética, y en protección radiológica. He participado en dos proyectos europeos con financiación de la UE (BIOCAPS FP7, SINFONIA H2020), seis proyectos de investigación nacionales con financiación pública (E-IMRT II, LOCALIZA, ARTFIBio, ARTFIbioDTS y HeNeBra) y en tres de ellos como IP o CoIP. Hasta diciembre de 2021 seré CoIP del proyecto HeNeBra y el IP del proyecto SINFONIA hasta septiembre de 2024 (es un proyecto europeo con 14 centros de investigación, liderado por John Damilakis, anterior presidente de EFOMP). También he colaborado en el proyecto europeo HERO llevado a cabo por la ESTRO en calidad de representante de la SEFM ante la ESTRO. Participo como investigador en el 2 ensayo clínico EORTC 1414 y en el subcontrato correspondiente al IISGS del proyecto Tatanka con la empresa SIVSA.

Como socio de la SEFM he participado como tesorero del congreso de Vigo y enlace con la ESTRO en el período 2015-2019 y en la actualidad soy representante de la SEFM en la EFOMP y continúo participando en la redacción del borrador del CORE CURRICULUM europeo del físico médico en radioterapia, elaborado de forma conjunta por la ESTRO y la EFOMP. También me han nombrado recientemente secretario del comité de asuntos europeos de la EFOMP.

Education

1978 – 1983                           University of Athens, Greece, graduate physicist

January 1989                         University of Heidelberg, Dr. sc. hum. in Medical Physics 

Professional Experience 

1983 – 1988                           Researcher, Heidelberg University, Clinical Radiology, Medical Physics

1989 – 1995                           Physicist and radiation protection commissioner, Darmstadt Clinic

1996 – 2015                           Head of Medical Physics & Engineering, Radiation Oncology, Klinikum Offenbach

2012 – 2015                           Radiation protection commissioner, Klinikum Offenbach 

Since November 2015           Professor (W3) for Medical Physics in Radiation Oncology Faculty of Medicine, Albert-Ludwigs-University of Freiburg

Since November 2015           Chair of Medical Physics Division, Radiation Oncology Department, University Medical Center Freiburg

Membership in Scientific Committees / Boards / Advisory Councils (Selection)

2013 – 2022                           Course director ESTRO Advanced Brachytherapy Physics 

Since  2018                            Associate Editor for Physica Medica

Since 2008                             Physics editor of the European brachytherapy periodical, Journal of Contemporary Brachytherapy

Since 2005                             Member of the scientific advisory board, Strahlentherapie und Onkologie, Journal of Radiation Oncology – Biology – Physics

Since 2023                             Member of the editorial board, Zeitschrift für Medizinische Physik

2019 – 2024                           President elect, president and vice-president of German Association of Medical Physics DGMP

2025                                       elected President of the European Federation of Organisations for Medical Physics (EFOMP), 2026 - 2029

Awards / Prizes 

1998                                      HERMANN HOLTHUSEN Prize by the German Society for Radiation Oncology (DEGRO)

2003                                      GfM Prize for technological development in radiation oncology 

2005                                      Invited lecture, New Technological Developments in Modern Brachytherapy, voted as Highlight of the 2005 DEGRO Congress 

2005                                      Honorary Scientific Associate, Nuclear and Particle Physics Section, Department of Physics, University of Athens, Greece

2007                                      HERMANN STREBEL MEDAL by the German, Austrian, and Swiss Radiation Oncology Societies (DEGRO, ÖGRO, SASRO) 

2011                                      Honorary member of the Austrian Society for Radiooncology, Radiobiology and Medical Physics (ÖGRO)

2014                                      ALFRED BREIT Prize of the German Society for Radiation Oncology (DEGRO)

2022                                      Innovation Award of the German Society for Radiation Oncology (DEGRO)

2026                                      Corresponding Member of the of the Hellenic Association of Medical Physicists (EFIE)

PubMed Link:                        https://pubmed.ncbi.nlm.nih.gov/?term=Baltas+D&sort=date

Citations 7963 (since 2021 2697)

h-index 49, i10-index 146

Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry from Toulouse University, France in 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM (National Institute of Health and Medical Research) since 1992 in Nantes, then in Toulouse (2011), and in Montpellier since 2021.

Manuel Bardiès was one of the founders of the EANM Dosimetry Committee (member from 2001 to 2013, chair 2009-2011). He chaired the EFOMP Science Committee between 2014 and 2016, and is the convenor and the current chair of the EFOMP Special Interest Group for Radionuclide Internal Dosimetry (SIGFRID).

He has been involved in education in various European structures (ESMIT, ESMPE). As coordinator of the Education Council of the French Society of Medical Physics for 10 years, he participated to the Board of the medical physics resident programme in France, and was appointed Professor by the French National Institute for Nuclear Science and Technology (INSTN) in June 2018 (renewed in June 2024).

The group led by Manuel Bardiès is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging or in the clinics. An important part of the research activity involves Monte Carlo modelling of radiation transport. The objective is to improve molecular radiotherapy by promoting patient-specific treatments (personalized medicine).